IMDX

Insight Molecular Diagnostics Inc.

IMDX.US imdxinc.com + Research + Basket
Employees 55
Phone 949 409 7600
Fiscal year end December
IPO Jan 04, 2016
Address 2 International Plaza Dr., Nashville, TN, United States, 37217
3.14
-0.03 (-0.79%)
USD · NASDAQ
52-week range
2.42
8.51
Trading at 12% of the 52-week range
Market Cap
103.41M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.65
Div. Yield
N/A
% Institutions
57.54%
% Insiders
21.00%

1 Year

-51.4%

3 Year

+35.3%

10 Year

-96.1%
Description

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Actions

Add an action for IMDX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Joshua Riggs President, CEO & Director 1983
Ms. Andrea Susan James Chief Financial Officer 1982
Mr. James Liu VP of Accounting, Treasurer, Controller & Principal Accounting Officer 1996
Mr. Yuh-Min Chiang Ph.D. Chief Technology Officer NA
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer NA
Mr. Peter Hong VP, General Counsel & Secretary NA
Mr. Steven Tahmooressi Vice President of Marketing NA
Ms. Sandra O'Donald Senior Vice President of Business Operations NA
Dr. Paul R. Billings FACP, M.D., Ph.D. Consulting Chief Medical Officer 1952
Dr. Michael D. West Ph.D. Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. 1953

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 20, 2026 Broadwood Partners, L.P. N/A Purchase 40.69K $3.88 $157.88K SEC
Apr 17, 2026 Broadwood Partners, L.P. N/A Purchase 40.11K $3.57 $143.21K SEC
Apr 16, 2026 Broadwood Partners, L.P. N/A Purchase 102.06K $3.45 $352.10K SEC
Feb 10, 2026 Broadwood Partners, L.P. N/A Purchase 521.74K $5.75 $3.00M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BROADWOOD CAPITAL Inc 12.68M Jun 30, 2026 38.76% $3.91 6.31%
Awm Investment Company Inc 2.84M Jun 30, 2026 8.67% $1.45 1.08%
Vanguard Capital Management, LLC 735.85K Jun 30, 2026 2.25% $0.00 36.99%
PURA VIDA INVESTMENTS, LLC 484.85K Jun 30, 2026 1.48% $7.73 -48.81%
Geode Capital Management, LLC 256.90K Jun 30, 2026 0.79% $0.00 -1.97%
FNY Investment Advisers, LLC 182.56K Jun 30, 2026 0.56% $0.39 -26.21%
Jane Street Group LLC 157.68K Jun 30, 2026 0.48% $0.00 0.00%
BlackRock Inc 150.52K Jun 30, 2026 0.46% $0.00 11.21%
Vanguard Fiduciary Trust Co 124.58K Jun 30, 2026 0.38% $0.00 -6.04%
State Street Corp 92.12K Jun 30, 2026 0.28% $0.00 81.51%
Millennium Management LLC 82.50K Jun 30, 2026 0.25% $0.00 -20.27%
UBS Group AG 53.28K Jun 30, 2026 0.16% $0.00 134.17%
Northern Trust Corp 49.09K Jun 30, 2026 0.15% $0.00 0.00%
Advisor Group Holdings, Inc. 39.14K Jun 30, 2026 0.12% $0.00 62.15%
Morgan Stanley - Brokerage Accounts 35.52K Jun 30, 2026 0.11% $0.00 -1.59%
683 Capital Management LLC 29.00K Mar 31, 2026 0.09% $0.01 -62.44%
Zevenbergen Capital Investments LLC 22.00K Sep 30, 2026 0.07% $0.00 0.00%
Jefferies Financial Group Inc 18.10K Jun 30, 2026 0.06% $0.00 0.00%
Marshall Wace Asset Management Ltd 16.60K Jun 30, 2026 0.05% $0.00 0.00%
ExodusPoint Capital Management, LP 14.03K Jun 30, 2026 0.04% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 475.41K 1.45% ▲ 0.00% Sep 30, 2026
2 Fidelity Extended Market Index 107.45K 0.33% ▼ 0.53% Aug 31, 2026
3 iShares Micro-Cap ETF 41.26K 0.13% ▼ 0.69% Sep 30, 2026
4 Fidelity Total Market Index 38.62K 0.12% ▲ 0.00% Aug 31, 2026
5 Fidelity Series Total Market Index 36.13K 0.11% ▲ 0.00% Aug 31, 2026
6 Vanguard U.S. Eq Idx £ Acc 12.92K 0.04% ▲ 123.69% Sep 30, 2026
7 Fidelity Nasdaq Composite Index 12.86K 0.04% ▼ 34.01% Aug 31, 2026
8 Vanguard Balanced Index Inv 7.93K 0.02% ▲ 0.00% Sep 30, 2026
9 1290 VT Micro Cap K 2.90K 0.01% ▲ 0.00% Aug 31, 2026
10 Victory Extended Market Index 1.17K 0.00% ▼ 20.22% Sep 30, 2026

Financial Highlights

▼
Market Cap: $103.41M
EBITDA: $-34.54M
Book Value: $-0.65
Earnings/Share: $-1.52
Profit Margin: 0.00%
Operating Margin: -3,815.06%
ROA (TTM): -57.82%
ROE (TTM): -23,603.11%
Revenue (TTM): $1.67M
Revenue/Share (TTM): $0.05
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -53.90%

Valuation Metrics

Enterprise Value: $83.04M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 32.72M
Shares Float: 9.98M
% Insiders: 21.00%
% Institutions: 57.54%
Short % Float: 5.98%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$4.06M
Cost of Goods Sold
adjust
$-3.87M
Gross Profit
subtotal
$190.00K
SG&A
adjust
$-10.63M
R&D
adjust
$-15.90M
Other Operating Expense
adjust
$-4.24M
Operating Income
subtotal
$-30.58M
Other / Non-Operating Items
adjust
$-19.64M
Net Income
subtotal
$-50.22M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IMDX.US!